Non-small-cell lung cancer and survivin −31G/C promoter polymorphism relation

Abstract

Background Lung cancer is known as one of the commonest cancers globally. It is considered an important cause of mortality all over the world. Survivin, a member of the family of inhibitor of apoptosis proteins, is involved in cell division regulation and apoptosis inhibition. The survivin gene is located on the human chromosome 17q25 and consists of 142 amino acids. Cancer risk was shown to be affected by the survivin promoter −31G/C genetic polymorphism. Such genetic variance was found to be associated with aberrant survivin expression in malignant cell at both protein and mRNA levels. One of the tumor suppressor gene is the p53 protein that induces cell apoptosis. Therefore, survivin polymorphism and p53 antibodies level association was considered in non-small-cell lung cancer (NSCLC). Aim To assess survivin promoter −31G/C polymorphisms in NSCLC, with detection of p53 antibodies level and the association between it and the gene polymorphism in those patients. Patients and methods In 2019–2020, a case–control designed research work was performed at Sohag University Hospital, Egypt. A total of 60 study participants were included in our study and categorized into 15 control group and 45 histopathologically confirmed NSCLC case group. The blood samples were collected into an EDTA tube and preserved frozen till DNA extraction. Results Our study shows a highly significant variation in the prevalence of the surviving gene promoter −31G/C polymorphism between cases and control groups (P<0.001). Moreover, regarding the level of p53 antibodies, it was higher in cases (17.01±5.97) than the control group (45.9±46.01), but the difference was not statistically significant (P=0.59). In our study, survivin −31G/C polymorphism was accompanied by epidermal growth factor receptor mutations detected in 33.3% of the cases, whereas 66.7% of the cases showed no mutation (wild type) of epidermal growth factor receptor. Conclusion Survivin promoter −31G/C gene polymorphism might have an association with lung cancer risk.